Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Rivaroxaban Tablet vs Granule in Healthy Japanese Males
NCT02537457Phase 1Completed
- Sponsor
- Bayer
- Start
- Jan 2014
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in embolism, Atrial fibrillation (AFib) and venous thrombosis (2 arms), sponsored by Bayer. Primary endpoints: Maximum observed drug concentration up to 3 days and Area under the concentration-time curve from time 0 to the last data point up to 3 days. Started Jan 2014; status: completed.
02
Drugs
rivaroxaban
03
Conditions
embolismAtrial fibrillation (AFib)venous thrombosis
Beyond the preview
Go deeper on NCT02537457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02537457.